Johnson & Johnson Plans to Buy Ollin Biosciences for Up to $3.4 Billion
Media reports say Johnson & Johnson is planning to acquire privately held Ollin Biosciences, an Austin-based developer of eye-disease therapies, for up to $3.4 billion.
Multiple media reports say that U.S. pharmaceutical giant Johnson & Johnson (JNJ) is planning to buy biotechnology firm Ollin Biosciences for up to $3.4 billion U.S.Based in Austin, Texas, privately held Ollin Biosciences develops therapies for treating eye diseases.Media reports say that Johnson…